FY2028 EPS Estimates for CRSP Decreased by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Brookline Capital Markets cut their FY2028 earnings per share estimates for CRISPR Therapeutics in a report released on Tuesday, May 5th. Brookline Capital Markets analyst L. Cann now forecasts that the company will earn $6.91 per share for the year, down from their previous estimate of $7.44. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($4.93) per share.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, May 5th. The company reported ($1.28) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.06). The company had revenue of $1.46 million for the quarter, compared to the consensus estimate of $6.06 million. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.53%. The firm’s revenue for the quarter was up 68.6% compared to the same quarter last year. During the same period last year, the company posted ($1.58) earnings per share.

CRSP has been the subject of several other reports. Morgan Stanley reiterated an “underweight” rating and set a $33.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. Bank of America reduced their price objective on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a research report on Thursday, January 22nd. Needham & Company LLC boosted their price objective on CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 13th. Citizens Jmp reduced their price objective on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a research report on Friday, January 30th. Finally, Truist Financial upgraded CRISPR Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $64.53.

CRISPR Therapeutics Trading Down 2.2%

NASDAQ:CRSP opened at $52.38 on Wednesday. The firm has a market capitalization of $5.05 billion, a PE ratio of -8.42 and a beta of 1.74. The stock has a 50 day moving average of $52.41 and a 200-day moving average of $54.60. CRISPR Therapeutics has a 52 week low of $33.03 and a 52 week high of $78.48.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC lifted its position in CRISPR Therapeutics by 7.5% in the fourth quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company’s stock worth $551,777,000 after purchasing an additional 735,084 shares during the period. Orbis Allan Gray Ltd lifted its position in CRISPR Therapeutics by 19.4% in the fourth quarter. Orbis Allan Gray Ltd now owns 5,950,145 shares of the company’s stock worth $312,026,000 after purchasing an additional 968,060 shares during the period. Capital International Investors lifted its position in CRISPR Therapeutics by 4.3% in the fourth quarter. Capital International Investors now owns 5,892,745 shares of the company’s stock worth $309,016,000 after purchasing an additional 243,487 shares during the period. State Street Corp lifted its position in CRISPR Therapeutics by 35.6% in the second quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after purchasing an additional 859,334 shares during the period. Finally, GSK plc acquired a new stake in CRISPR Therapeutics in the fourth quarter worth approximately $168,890,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 3,450 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $48.26, for a total transaction of $166,497.00. Following the completion of the transaction, the general counsel directly owned 91,240 shares in the company, valued at approximately $4,403,242.40. The trade was a 3.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Naimish Patel sold 3,150 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $48.26, for a total value of $152,019.00. Following the completion of the sale, the insider owned 13,143 shares of the company’s stock, valued at $634,281.18. This trade represents a 19.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 51,828 shares of company stock worth $2,578,097. Company insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.